We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Lauren Harshman

Lauren C Harshman MD

Assistant Professor of Medicine, Oncology, Harvard Medical School; Co-director of the Kidney Cancer Program at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, MA

Assistant Professor of Medicine, Oncology, Harvard Medical School; Co-director of the Kidney Cancer Program at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, MA. She is the study chair for the phase 3 PROSPER RCC Trial investigating perioperative nivolumab in non-metastatic RCC including those with sarcomatoid differentiation.

Disclosures

Dr. Harshman's disclosures for last 36 months:

Advisory: Bayer, Genentech, Dendreon, Pfizer, Medivation/Astellas, Kew Group, Theragene, Corvus, Merck;   (Exelixis after next week)

Research to the institution: Bayer, Sotio, Bristol-Myers Squib, Merck, Takeda, Dendreon/Valient, Jannsen, Medivation/Astellas, Genentech, Pfizer; 

CME: PER, Applied Clinical Education

Travel: Sanofi,  Bayer